A couple weeks ago, I went to C2E2, a comic book convention in Chicago. It’s a relatively new con – just four years young. It’s definitely a step up from the longer-running Wizard World, just in terms of publishers, artists and guests they get. Which, unfortunately for my wallet, makes it that much easier to splurge on books.
I ended up coming away with four trade paperbacks, which is a solid afternoon or evening of reading material. Rather than do full-blown reviews of each, I’ll do a sentence or two review that lets you know exactly what you need to know.
The Walking Dead Vol. 16: A Larger World – Even though I love this series, it’s failed to explore new territory in the past few trades. While it took a whole trade to get there, I think 16 is going to push the series back into interesting territory. Rick finds a new group of people to distrust, but in finding them, he may have discovered a way to create a world that’s truly safe. This was still slow, but I was satisfied with the ending.
3 of 5 stars
The Walking Dead Vol. 17: Something to Fear – If they’re setting up another arc on par with the Governor with Negan’s character, I’m in. This issue was brutal, reveals just how difficult Rick’s vision is going to be to achieve, and reminds us of how hard the choices in this world are. This trade felt a lot closer to the stories that made me fall in love with the series, so hopefully they continue to play with these themes.
4 of 5 stars
Lucid Vol. 1 – This story felt extremely disjointed to me, nothing more than a series of wise-cracking characters with shallow motivations and dark sides. When I flipped through the book at Achaia’s booth, the art and concept seemed interesting, but this is just one of those books that falls apart upon closer inspection. I don’t know if they’re planning on serializing this with more stories, but I probably won’t be back to check it out.
1 of 5 stars
Syndrome: The polished art in this book is really well done – it’s not genre-bending or boundary-pushing, but just plain solid, traditional execution. I found quite a few of the characters intriguing, especially the art director and the actress, but at the end of the book I was left wanting more from them. The concept behind the book is that a researcher and Branson-esque billionaire are trying to cure the evil side of human nature, and their methodology is ripe for lots of great storytelling, but at the end of this book, I felt like the ending was abrupt and trivialized the plot, in a way. Again, not sure if this book will continue with more arcs, but I’ll definitely check it out if they do.
4 of 5 stars